sorafenib has been researched along with cambinol in 1 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (cambinol) | Trials (cambinol) | Recent Studies (post-2010) (cambinol) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 53 | 0 | 42 |
| Protein | Taxonomy | sorafenib (IC50) | cambinol (IC50) |
|---|---|---|---|
| NAD-dependent protein deacetylase sirtuin-1 | Homo sapiens (human) | 8.85 | |
| Sphingomyelin phosphodiesterase 3 | Homo sapiens (human) | 5 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alvarez, ML; Angel, A; Carrillo, MC; Ceballos, MP; Comanzo, CG; Delprato, CB; Ferretti, AC; Livore, VI; Lucci, A; Mottino, AD; Quiroga, AD | 1 |
1 other study(ies) available for sorafenib and cambinol
| Article | Year |
|---|---|
Sirtuin 1 and 2 inhibitors enhance the inhibitory effect of sorafenib in hepatocellular carcinoma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; ATP Binding Cassette Transporter, Subfamily G, Member 2; Carbazoles; Carcinoma, Hepatocellular; Cell Cycle Proteins; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Hep G2 Cells; Histone Deacetylase Inhibitors; Humans; Liver Neoplasms; Multidrug Resistance-Associated Proteins; Naphthalenes; Neoplasm Invasiveness; Neoplasm Proteins; Pyrimidinones; Signal Transduction; Sirtuin 1; Sirtuin 2; Sorafenib; Spheroids, Cellular | 2021 |